Experience

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare Company, Inc. of $450 million aggregate principal amount of its 5…

Davis Polk advised the representatives of the underwriters, in connection with the offering of $4.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $124.7 million SEC-registered offering of 28,503,220 shares of…

Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA Biosciences, Inc. at $15.00 per share, for total gross proceeds of …

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an aggregate price to the public of approximately $89.4 million,…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…